News | April 01, 2025
Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
AstraZeneca Pharma India discontinues manufacturing of Imdur
AstraZeneca Pharma India discontinues manufacturing of Imdur
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Offers affordable, high-quality solutions for diabetes care
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Subscribe To Our Newsletter & Stay Updated
